Navigation Links
Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
Date:7/21/2011

ompany dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 180 products in more than 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events.  These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts.  You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon, such as those set forth in its reports on Form 8-K, 10-Q and 10-K fi
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Shareholders Approve Acquisition by Teva
2. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
3. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
4. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
5. Cephalon Lodges Bidders Statement for A$167 Million Offer for ChemGenex Pharmaceuticals
6. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
7. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
8. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
9. Cephalon Wins FENTORA Patent Suit Against Watson
10. Cephalon Announces Definitive Agreement to Acquire Gemin X
11. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... --  West Pharmaceutical Services, Inc. (NYSE: ... injectable drug administration, announced today it plans to expand ... in Waterford, Ireland . The new ... and other high-value packaging components, in order to meet ... this new site could bring approximately 150 new jobs ...
(Date:10/2/2014)... BOSTON , Oct. 1, 2014   Intarcia ... two of its four phase 3 clinical trials for ... through a matchstick-sized, subcutaneous osmotic mini-pump). The first trial, ... that tested the efficacy and safety of ITCA 650 ... study demonstrated ITCA 650 to be significantly superior to ...
(Date:10/1/2014)... Ohio , Oct. 1, 2014 /PRNewswire/ ... shareholders is now available. Interested parties can learn ... how Cardinal Health is supporting the health ... http://cardinalhealth.com/annualreport . Photo- ... to summary financials and the chief executive ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2
... -- Global Information, Inc. is excited to announce remaining ... scheduled for Boston, MA in the Spring of 2012. ... Drug Design Conference June 6 - ... to arrive at its current mainstream position in medicinal chemistry, ...
... developer of Healthcare Technology Networks ("HTN") designed to improve ... announces the launch of its proprietary Opioid Management Program ... United States Bone & Joint Decade , from ... from musculoskeletal disease filled 1.6 billion prescriptions. While 18.6 ...
Cached Medicine Technology:Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27 2Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27 3Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3
... America (GSA) the nation,s largest interdisciplinary organization ... Vishwa Deep Dixit, DVM, PhD, of the Pennington Biomedical ... Shock New Investigator Award. The distinguished honor is ... through basic biological research. It was established in 1986 ...
... The immunochemical fecal occult blood test (iFOBT) is ... not in the upper gastrointestinal (GI) tract, confirms a ... Journal ) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf . ... noninvasive tool to screen for bleeding without symptoms in ...
... Hydrogen sulfide is a foul-smelling gas with an odor resembling ... substance is generally associated with decaying vegetation, sewers and noxious ... it also plays a critical role in protecting blood ... study from the University of Texas Medical Branch at Galveston. ...
... By Denise Mann HealthDay Reporter , TUESDAY, Aug. ... and replace damaged discs -- at least in rats, a ... implants like these, made of cells and collagen, may one day ... They might also last longer than the more artificial replacement ...
... of Nottingham scientist who uses fruit flies to study the ... Research UK. Dr Marios Georgiou, lecturer in cell biology ... a five year Career Establishment Award of 600,000. The award ... to become the eminent cancer scientists of the future. ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... leading pulmonary associations have issued new guidelines for the ... of the world,s leading killers. While the recommendations ... they differ little from previous guidelines and are meant ...
Cached Medicine News:Health News:Dixit to receive GSA's 2011 Nathan Shock New Investigator Award 2Health News:Noninvasive fecal occult blood test effective screen for lower GI tract lesions 2Health News:Scientists show 'swamp gas' protects blood vessels from complications of diabetes 2Health News:Bio-Engineered Spinal Discs Appear Successful in Rats 2Health News:Bio-Engineered Spinal Discs Appear Successful in Rats 3Health News:Nottingham scientist wins major cancer research award 2Health News:Nottingham scientist wins major cancer research award 3Health News:New Guidelines for Spotting, Treating COPD Released 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... The AFX (Air Fluid eXchange) ... lens designed for use in ... to its use as a ... the low profile and sutureless ...
... The 45° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
Medicine Products: